Chicago Partners Investment Group
BBIO icon

Chicago Partners Investment Group’s BridgeBio Pharma BBIO Stock Holding History

Chicago Partners Investment Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Buy
+3,535
New +$248K 0.01% 1256
2021
Q1 		– Sell
-2,883
Closed -$200K – 523
2020
Q4 		$200K Buy
+2,883
New +$139K 0.02% 442

Other funds holding BBIO

Jupiter Topco
Jupiter Topco New York $245B AUM
Kohlberg Kravis Roberts & Co
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Chicago Partners Investment Group's BBIO Position: Q2 2026 in Review

Chicago Partners Investment Group opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 3,535 shares worth $293K. The stake represents 0.01% of the portfolio and ranks #1256 among its holdings. This is a return to the name: Chicago Partners Investment Group previously reported a position in BBIO as recently as Q4 2020.

Chicago Partners Investment Group first reported a position in BBIO in Q4 2020 and has held it in 2 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Chicago Partners Investment Group held 3,535 shares of BridgeBio Pharma worth $293K as of Q2 2026.
  • BridgeBio Pharma was a new Chicago Partners Investment Group position in Q2 2026.
  • BridgeBio Pharma made up 0.01% of Chicago Partners Investment Group's portfolio in Q2 2026, its #1256 holding.
  • Chicago Partners Investment Group first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 2 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Chicago Partners Investment Group's 13F filing for Q2 2026, filed 30 Jul 2026.